Age-related changes in memory and effector T cells responding to influenza A/H3N2 and pandemic A/H1N1 strains in humans

Xin Zhoua, Janet E. McElhaneya,b,*

a Center for Immunotherapy of Cancer and Infectious Diseases, Department of Immunology, University of Connecticut School of Medicine, Farmington, CT 06030-1601, USA
b Department of Medicine, University of British Columbia, Vancouver, BC, Canada V5Z 1L8

1. Introduction

Thymic involution and a decline in T cell output with advancing age, together with a lifetime of exposure to a variety of pathogens, leads to a dramatic reduction in the naïve T cell pool and a relative increase in the proportion of memory T cells. The most dramatic functional changes occur in the CD8+ T cell subset, where progressive exhaustion of this compartment leads to terminal differentiation of the memory T cells responding to a particular pathogen [1]. Influenza, particularly A/H3N2 strains, is foremost among all infectious diseases in the age-related increase in risk for serious complications and death [2,3]. Although influenza vaccination is the first and most important step in protecting against influenza infections, particularly those with high-risk conditions [6]. These observations suggest that T-cell mediated clinical protection against complicated influenza illness is important when antibodies fail to provide sterilizing immunity against infection.

Our previous studies in vaccinated older adults have shown that measures of cell-mediated immunity are important indicators of clinical protection against illness from an influenza infection [7,8]. These results are consistent with earlier findings showing that cytotoxic T lymphocytes (CTL) are important for recovery from influenza infection [9]. Granzyme B (GzmB) has been shown to be a key cytolytic mediator of killing of influenza-infected host cells [10–12]. Low levels of GzmB activity are associated with increased risk of influenza illness in older adults but in contrast to young adults, GzmB appears to be non-specifically expressed within a subset of CD8+ T cells in older adults [7,8]. Thus, the identification of the phenotype of T cells that provide an influenza virus-specific cytolytic response is important for a mechanistic understanding of the correlates of clinical protection against influenza illness in the over 65 population.

As the pool of naïve and early memory T-cells declines with aging, T cells with a naïve phenotype (CD45RA+) exhibit numerous functional defects, mainly their reduced ability to expand and dif-
ferentiate into virus-specific effector cells [13]. While these changes have been well documented in a number of experimental models of human PBMC, their impact on the response to live influenza virus challenge has yet to be studied. The purpose of this study was to elucidate age-related changes in the cytolytic T cell response to both influenza A/H3N2 and pH1N1 virus within the memory and effector subsets of CD4+ and CD8+ T cells. Our data show that in older adults, cytolytic activity against influenza-infected targets is severely compromised in CD8+ T cells but preserved in CD4+ T cell subsets when compared to young adults. Further, A/H3N2 strains elicit a greater cytolytic response than pH1N1 in all age groups studied and is consistent with the observed increase in serious complication rates of pH1N1 infection. These results suggest that CD4+ T cells may provide a compensatory response to influenza as a potential mechanism of protection against influenza illness when CD8+ T cells become dysfunctional in older adults.

2. Materials and methods

2.1. Study design and participants

Fifteen young (20–25 years old) and older adults (60–70 years old or >80 years old) from the vicinity of the Greater Hartford Area of Connecticut were studied pre-vaccination and 4-weeks and 10-weeks post-vaccination in the fall and winter of 2008–2009. All subjects were recruited through written informed consent. The Institutional Review Board of the University of Connecticut Health Center approved the protocol and informed consent document. Subjects were excluded for an acute respiratory illness in the 2 weeks preceding study enrolment, insulin-requiring diabetes, any conditions or medication causing immunosuppression such as prednisone >10 mg/day, or any contraindications to influenza vaccination.

2.2. Cell culture and virus stimulation

Human PBMCs were isolated from venous blood samples by Histopaque gradient purification and stimulated in 0.5 ml of AIM V media (GIBCO) containing 1.0 x 10^6 PBMC and 4 x 10^5 TCID50 of influenza A/Victoria/3/75 (H3N2) virus as previously described [7] or stimulated with pandemic influenza A/TN/1-560-09 (pH1N1) virus (Generous gift from Dr. Richard J. Webby’s Lab, St. Jude Children’s Research Hospital, Memphis). For proliferation and/or cytotoxicity assays, cells were stimulated with influenza virus 5 days or 5 μg/ml phytohemagglutinin (PHA) for 6h and cultured in AIM V medium containing 10% human AB serum (Sigma) (R&D Systems).

2.3. Flow cytometry and antibodies

To determine the phenotype of T cells responding to influenza challenge, PBMCs were prepared and stained as previously described [8]. Briefly, human anti-CD107a-PE (HA43) was added to the PBMC/virus cultures, incubated for 12h, then the cells were washed with cold 0.2% FBS/PBS twice before adding the following conjugated monoclonal antibodies: human anti-CD8–FITC (OKT8) and anti-CD25–APC-Cy7 (eBioscience), anti-CD127–Biotin/PE-Texas Red and anti-CCR7 PE-Cy7 (3D12) (BD Pharmingen), anti-CD4 Alex Fluor 700 (OKT4) and anti-CD45RA Pacific Blue/or eFluor 450 (HI100) (eBioscience). For intracellular staining, cells were fixed with 2% paraformaldehyde and permeabilized with permeabilization buffer (eBioscience), then incubated with anti-GzmB Alex Fluor 647 (GB11) or anti-Perforin PE (GB9) (BD Pharmingen) antibodies. For cell sorting, human PBMCs were prepared as above and sorted by using FACS Vantage SE/DIVA High Speed Sorter (BD Biosciences) running DIVA 5.0 Software. Data were acquired on the BD LSR II, and analysis using FlowJo 8.8.2 software.

2.4. Cytotoxicity assay

Human PBMCs were prepared and cultured in AIM V medium containing 10% human AB serum (Sigma) with influenza A/Victoria/3/75 or A/TN/1-560-09 (pH1N1) virus stimulation for 5–6 days. CD4+ and CD8+ T cells were selected by bead separation (Dyna Beads) and sorted into the different memory/effector subsets before the assay. PHA-activated autologous lymphoblast target cells were infected and cultured with influenza H3N2 or pH1N1 virus for 30 min and added into V-bottom 96-well plate at the dilution of 10^4 cells/100 μl per well in triplicate before adding sorted effector T-cell subsets at E/T (effector/target) ratios of 10:1 and 5:1; co-cultures were incubated for 4h at 37°C [14,15]. The lactate dehydrogenase (LDH) activity released in the cell free supernatants was determined using the CytoTox 96® Non-Radioactive Cytotoxicity Assay (Promega, Madison, WI).

2.5. Proliferation assay

The proliferative response to influenza was assessed by the MTT Cell Proliferation Assay (ATCC), based on the reduction of MTT (3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide) by mitochondrial dehydrogenase of intact cells to formazan (MTT metabolic product). Briefly, human PBMCs were stimulated with influenza virus for 5–6 days in AIM V medium containing 10% human AB serum. Sorted CD4+ and CD8+ T cell subsets were added to a flat bottom 96-well microtiter plate (1 x 10^5 cells/100 μl per well) with 10 μl of MTT reagent, incubated for 3–4h, and then 100 μl of Detergent Reagent added and incubated in the dark for 4h at RT. The amount of formazan produced (A570) was used to quantify the proliferative response.

2.6. Statistical analysis

Unpaired t tests were used to compare the two groups for the different CD4+ and CD8+ T-cell subsets. Analyses were performed using Origin Pro 8.0 (OriginLab, MA, www.OriginLab.com). p values <0.05 were considered statistically significant.

3. Results

3.1. A phenotype shift in T cell subsets in vaccinated older compared to young adults

To determine the effect of age on the phenotype of naïve, memory and effector T lymphocytes responding to influenza challenge, PBMCs from three age groups: 20–25 years old (yo), 60–70 yo, and >80 yo, were stimulated for 20h with live influenza A/H3N2 virus and analyzed by flow cytometry according to CD45RA+CCR7+ (naïve), CD45RA–CCR7+ (central memory), CD45RA–CCR7− (effector memory) and CD45RA+CCR7− (effector) subsets (Fig. 1A) [16]. Consistent with contraction of the peripheral naïve T cell pool and the effect of aging on CD4+ and CD8+ T cells [17], there was a significant decline with age in the proportion of naïve (CD45RA+CCR7+) CD4+ and CD8+ T cells (Fig. 1A–C, p < 0.0001). The reciprocal increase in the proportion of different memory and effector subsets varied across the CD4+ and CD8+ T cell subsets.

In CD4+ T cells, the proportion of central memory T cells increased with age (Fig. 1B, p < 0.0001) but in the older adult groups, there was an associated significant decline in the proportion of effector memory (CD45RA–CCR7−) and effector (CD45RA+CCR7−) CD4+ T cells in the >80 yo age group relative to the 60–70 yo age
Fig. 1. The phenotype shift and the dual expression of GzmB and Perf delineates age-related changes in different T cell subsets. PBMCs from healthy young (HY, light or yellow bars) and older (HO, 60–70 years old, dark or green bars, and HQ, >80 years old, striped bars, grey or blue) adults (n=15/group) obtained at 4 or 10 weeks post-vaccination were cultured with live influenza virus for 20 h. (A) CD4+ and CD8+ subsets were defined by the expression of cell surface molecules, CD45RA and CCR7, and their intracellular cytolytic effector molecules, GzmB and Perf. The percentage of cells within each of the T-cell subsets: CD45RA+CCR7+ (naive), CD45RA−CCR7+ (central memory, CM), CD45RA−CCR7− (effector memory, EM), and CD45RA+CCR7− (effector) are shown. The proportion of naïve T cells decline with age while different memory and effector subsets increase with age in (B) CD4+ and (C) CD8+ subsets. The proportion of effector T cells that are GrzB+ increase with age in both CD4+ and CD8+ subsets. In contrast, the proportion of GzmB+Perf+ effector T cells are similar between age groups in both (D) CD4+, and (E) CD8+ subsets at 4 weeks post-vaccination but declined with age by (F) 10 weeks post-vaccination in both CD4+ and CD8+ T cell subsets. Error bars represent standard error of the mean. Significant differences in the means between age groups are shown as *p<0.0001, **p=0.001, and ***p<0.001.
group (Fig. 1B). In contrast, CD8+ T cell subsets [Fig. 1C] showed an age-related increase in the proportion of central memory (p < 0.0001), effector memory (p < 0.0001) and effector (p = 0.001) T cells. These results show that contraction of the naïve T cell pool with aging is associated with CD4+ T cell expansion mainly in the central memory subset. In contrast, CD8+ memory T cells are more differentiated to effector memory and effector T cells, which is consistent with aging having its greatest impact on the CD8+ T cell subset.

3.2. Effect of age on effector T cells expressing GzmB and perforin

The next experiments evaluated the effect of age on the cytolytic effector function of different T-cell subsets. Previous studies have shown that perforin (Perf) and GzmB are key cytolytic effector molecules, which are stored in the granules of cytolytic T cells [18,19]. Upon T cell receptor binding to the peptide–MHC I complex, granules containing granzymes and Perf migrate to the cell surface and are released from the CTL. Perf facilitates the entry of GzmB into virus-infected host cells to cause apoptotic cell death, and thus is necessary for effective cytolytic activity. Thus, we analyzed the intracellular expression of effector molecules, GzmB and Perf, in different CD4+ or CD8+ T-cell subsets (Fig. 1A) to estimate their cytolytic potential in response to live influenza virus.

In CD4+ T cells, GzmB was expressed only in the effector (CD45RA+CCR7−) subset (Fig. 1D), while in CD8+ T cells, GzmB was expressed in a subset of all memory and effector cells (Fig. 1E) as has been previously shown [20]. The proportion of GzmB+ cells increased with age in these virus-stimulated CD4+ and CD8+ T cell subsets (Fig. 1D, E) but the proportion was greater in CD8+ T cells and there was a plateau with no further increase from the 60–70 yo to the >80 yo age group (Fig. 1D, E). However, our previous results showed that a large proportion of CD45RA+CD8+ T cells from older adults express GzmB at baseline and these GzmB+CD8+ T cells respond poorly to virus stimulation [8], consistent with a terminally differentiated phenotype [1]. To further distinguish the phenotype of cytolytic T cells responding to influenza virus, we evaluated these T cell subsets for the co-expression of GzmB and Perf in influenza-stimulated PBMC. A response to vaccination was detected but the increase in the proportions of GzmB+Perf+ T cells in CD4+ and CD8+ subsets was not statistically significant due to the high variability in the proportions of GzmB+Perf+ T cells in pre-vaccination samples (Supplemental Fig. 1). At 4-weeks post-vaccination, the proportion of effector CD4+ T cells that co-expressed GzmB and Perf was similar across the three age groups and to the proportion of GzmB+ effector CD4+ T cells in young adults (Fig. 1D).

In contrast, the CD8+ T cell subset showed a statistically significant reduction in the proportion of effector T cells that were GzmB+Perf− compared to GzmB+ alone (Fig. 1E, p < 0.0001). While young and older adults had similar proportions of GzmB+Perf+ effector CD8+ T cells at 4-weeks post-vaccination, there was a significant age-related decline in the proportion of GzmB+Perf+ effector T cells by 10-weeks post-vaccination (Fig. 1F), which was more marked in the CD8+ T cells compared to CD4+ T cells. These results show an age-related shift in the relative proportion of GzmB+Perf− effector T cells responding to influenza challenge within the CD4+ and CD8+ subsets such that CD4+ T cells are the main source of effector T cells by 10-weeks post-vaccination in older adults. Since the influenza season usually occurs after 10-weeks post-vaccination, these data suggest that this decline in the effector T cell response to influenza challenge is clinically important with respect to serious outcomes of influenza infection [21].

3.3. Degranulation markers of cytotoxic effector function in response to virus stimulation

Our previous experiments showed that older adults (mainly those with congestive heart failure) who showed an increased proportion of GzmB+CD8+ T cells expressing the degranulation marker, CD107a, at baseline, mounted a poor response to influenza virus stimulation [8,22]. In contrast, healthy older compared to young adults showed an increased proportion of GzmB+CD107a+CD8+ T cells in the response to influenza virus. Thus, we were interested in whether the relative changes in GzmB+Perf+ T cells within the CD4+ and CD8+ subsets of influenza-stimulated PBMC could be detected using CD107a. As in our previous study, healthy young and older adults showed similar proportions of CD8+ T cells (and CD4+ T cells in this study) that were CD107a+ after 12 h of virus stimulation. Thus, we were interested in measuring degranulating activity in the response to live influenza virus (12-h stimulation) within each of the memory and effector T-cell subsets using cell surface expression of CD107a (Fig. 2). Young and older adult PBMC showed similar proportions of degranulating cells (CD107a+) within the memory and effector GzmB+CD4+ T-cell subsets (Fig. 2). However, older compared to young adults showed a significant increase in the proportion of GzmB+CD8+ T cells expressing CD107a; the increase was >20% in the central memory and >30% in effector memory and effector subsets (p < 0.001 for all comparisons) (Fig. 2). These results suggest that a larger proportion of CD8+ T cells were activated to mount a cytolytic response to influenza virus challenge. A functional assay of cytolytic activity was therefore conducted to confirm these results.

3.4. Cytolytic activity in virus-specific CD4+ and CD8+ effector T-cell subsets

To further investigate the cytolytic function of different T-cell subsets responding to influenza virus, cytotoxicity assays were
performed. CD4+ or CD8+ T cells were stimulated with H3N2, sorted into the different memory and effector T-cell subsets, and then used as effector cells (E) in cytotoxicity assays with PHA-stimulated, autologous PBMCs infected with influenza virus as target cells (T) (Fig. 3). Results are reported as % specific lysis at an E:T ratio = 10:1. There was no cytolytic activity detected in unstimulated PBMC. In virus-stimulated CD4+ T cells from young and older (60–75 years old) adults, we found similar levels of cytolytic activity in the effector (CD45RA+CCR7−) and effector memory (CD45RA−CCR7−) subsets at 4 weeks (Fig. 3A) and 10-weeks (Fig. 3B) post-vaccination. In contrast, young compared to older adults exhibited significantly higher cytolytic activity in CD8+ T cells within the effector memory (p < 0.01) and effector (p < 0.005) subsets at 4-weeks post-vaccination (Fig. 3A). By 10 weeks post-vaccination, there was a significant further decline in influenza virus-specific cytolytic activity of effector CD8+ T cells in older compared to young adults (Fig. 3B, p < 0.005). A corresponding diminished proliferative response in older compared to young adults after five days of stimulation with the A/H3N2 strain was demonstrated in the CD8+ effector T-cell subset (Supplemental Fig. 2).

Taken together, these results suggest that a split (killed) virus vaccine stimulates a more sustained memory T-cell response in the CD4+ relative to the CD8+ subset. While similar proportions of GzmB+Perf+ effector (CD45RA+CCR7−) T cells can be stimulated in both CD4+ and CD8+ T-cell subsets in young and older adults at 4-weeks post-vaccination, there is a decline in this effector CD8+ T-cell subset by 10-weeks post-vaccination in older adults. In addition, significantly lower levels of cytolytic activity in effector CD8+ T cells in older compared to young adults at 4-weeks post-vaccination, and a further reduction in older adults by 10 weeks post-vaccination are evidence of functional defects in the CD8+ T-cell response. In contrast, cytolytic activity in CD4+ effector T cells was similar in young and older adults and sustained from 4-weeks to 10-weeks post-vaccination in effector CD4+ T cells; although the frequency of this T-cell subset declined by 10-weeks post-vaccination in older adults but was not as marked as in the CD8+ T-cell subset. Overall, a more sustained memory CD4+ T-cell response was elicited by influenza vaccination in older adults while the response to vaccination was sustained in both CD4+ and CD8+ subsets in young adults.

3.5. Phenotype of virus-specific cytotoxic T cells in vaccinated young and older adults

In this study, we distinguished the T-cell subsets and evaluated their effector function based on T-cell surface markers CD45RA and CCR7 as well as effector molecules, GzmB and Perf, and related cytolytic activity. We found that effector T cells that become GzmB+Perf+ in response to influenza challenge, are the T cells with high cytolytic activity against influenza-infected targets. We were next interested in further characterizing the phenotype of the GzmB+Perf+ T cells responding to influenza stimulation. Since the expression of IL-7 receptor alpha (IL-7Rα) can distinguish functional subsets of CD8+ T cells specific for different respiratory viruses in humans [23], we used antibody to CD127 (IL-7Rα) in this analysis. In our study, most of the effector T cells (GzmB+Perf+) expressed CD127 and could be further separated into two groups based on expression of the surface marker, CD25 (IL-2 receptor) (Fig. 4A). The CD25+ effector T-cell subset we identified has the phenotype, CD45RA−CCR7−CD25+CD127+, which is consistent with high proliferative capacity in response to A/H3N2 compared to pH1N1 in the CD25+ subset, and to both strains in the CD25−subset (Fig. 4D). Comparable levels of cytolytic activity on a per cell basis were generated in the CD25+ subset in response to H3N2 and pH1N1 strains (Fig. 4E), whereas the CD25−subset had ~50% of the cytolytic activity in the CD25+ subset (data not shown).

3.6. Effector T cell response to A/H3N2 vs. pH1N1 after seasonal influenza vaccination

In this study, we were also interested in comparing the proliferative and cytolytic T-cell response to A/H3N2 and pH1N1 within the effector T-cell subset (CD45RA+CCR7−). Since A/H3N2, A/H1N1, and pH1N1 strains share some T-cell epitopes within the internal proteins derived from the virus [20], seasonal vaccine could stimulate a T-cell response to A/H3N2 and pH1N1 strains. These experiments specifically focused on the phenotype of the effector T-cell subset after 20 h of virus stimulation, and the proliferative and CTL response after in vitro stimulation (5–6 days) with live influenza virus. No changes in the T-cell phenotypes were observed from 20 h to 5–6 days of in vitro stimulation. All CD45RA+CCR7−GzmB+Perf+ T cells were CD127+ but there was a significantly lower proportion of effector T cells that were CD25+ in pH1N1 vs. A/H3N2-stimulated PBMC (p < 0.001) (Fig. 4A and B, p < 0.001), and a corresponding higher proportion of CD25−effector T cells in both CD4+ and CD8+ subsets (Fig. 4C). The lower proliferative response stimulated by the pH1N1 compared to the A/H3N2 strains is demonstrated in the CD25+ subsets of CD4+ and CD8+ effector T cells from young adults (Fig. 4D), and is associated with lower cytolytic activity within the effector (CD45RA+CCR7−)
subsets of CD4+ (p < 0.01) and CD8+ (p < 0.005) T cells (Fig. 4E). The CD25+CD127+ effector subsets of CD4+ or CD8+ T cells from young adults exhibited similar levels of cytolytic activity against A/H3N2 and pH1N1-infected targets following stimulation with live virus (Fig. 4E). The proportion of CD25+CD127+ effector T cells responding to A/H3N2 and pH1N1 strains significantly declined with advancing age group in both the CD4+ (p < 0.001) and CD8+ (p < 0.001) T-cell subsets (Fig. 4F). Compared to the influenza A/H3N2 strain, there was a very limited CD25+ effector CD8+ T cell response to pH1N1 stimulation in both older age groups with no statistical difference observed between the two subtypes (less than 3% of total effector GzmB+Perf+ T cells) (Fig. 4F).

These results suggest that the main phenotype of CD4+ and CD8+ T cells responding to influenza virus is within the CD45RA+CCR7−CD25+CD127+ subset. In other words, these are the cells that express IL-2R (CD25) and thus have recently undergone proliferation and have the highest level of cytolytic activity. Once these T cells become CD25−, their cytolytic activity declines to approximately 50% of the CD25+ effector T cells suggesting that they are becoming exhausted. The expression of IL-7R (CD127) is consistent with the phenotype of influenza-specific CD8+ T cells in PBMC [24] and presumably the phenotype of T cells responding to dendritic cells or macrophages presenting influenza-derived peptides in PBMC cultures. Activation of these CD8+ T cells in the lungs has been characterized by a reduction in the expression of IL-7R [24]. Sustained with live influenza virus A/H3N2 (light bars) or pH1N1 (dark bars) for 5–6 days. (A) In HY, CD4+ and CD8+ subsets that were GzmB+Perf− were defined by the expression of cell surface molecules, CD45RA, CCR7, CD25, CD127. Differences in the response to pH1N1 vs. A/H3N2 are shown as ***p < 0.001, *p < 0.01, and **p < 0.05 in (B) through (F). The effectors (CD45RA+CCR7+CD127+) subsets of CD4+ and CD8+ for (B) CD25+ and (C) CD25− T cells are shown for HY. The proportion of effector T cells in CD25+ subset was significantly lower in pH1N1 compared to A/H3N2-stimulated PBMC for both CD4+ and CD8+ T cells. (D) PBMCs from HY were stimulated with influenza A/H3N2 or pH1N1 live virus for 5–6 days, then CD4+ or CD8+ cells were stained with CD45RA+CCR7−CD25+CD127+ and CD45RA+CCR7−CD25−CD127+ T-cell subsets were sorted, and proliferation assays were performed. The proliferative response was significantly higher in the CD25+ compared to the CD25− in the CD4+ and CD8+ effector T cell subsets. (E) PBMCs from young adults were stimulated with live virus for 5 days, sorted and prepared as effectors (E), or stimulated with PHA for autologous targets (T) for assays of cytotoxicity as in Fig. 3 (n = 6/group). Cytotoxicity was calculated as mean % specific lysis for E:T ratios of 5:1. (F) PBMCs from HY and HO, 60–70 yo or >75 yo, were stimulated for 5–6 days with A/H3N2 or pH1N1 and the effectors (CD45RA+CCR7+CD25+CD127+) T cell response compared across the different aged groups and stimulating viruses. An age-related decline in both CD4+ and CD8+ effector T cell responses and diminished response to pH1N1 vs. A/H3N2 was observed. Error bars represent standard error of the mean.
activity of the central memory (CD45RA+CCR7+T) CD8+ T-cell subset in older adults suggests that this subset contains CD8+ T cells that do not behave as true central memory T cells and represent a phenotype shift with aging. Future experiments will further delineate the phenotype of these central memory CD8+ T cells and determine age-related changes in their function.

The identification of influenza virus-specific CTL (GzmB+Perf+) using the degranulating marker, CD107a, unexpectedly yielded a large proportion of GzmB+CD8+ T cells that expressed CD107a in older adults. Functional assays confirmed the reduction in cytolytic activity in CD8+ T cells responding to influenza challenge. These results suggest that the cytolytic potential on a per cell basis is reduced in influenza-specific CD8+ T cells of healthy older adults. In addition, a significant fraction of these CD8+ T cells may be approaching a terminally differentiated state, as we had previously shown that CD45RA+GzmB+CD8+ T cells mount a poor response to influenza virus [9]. Recent studies suggest that a significant portion of the CD45RA+CD8+ T cells that accumulate with aging are due to the T cell response to chronic viral infections such as CMV [1]. With continuous exposure to the virus, these CMV-specific T cells are driven to become terminally differentiated T cells, preferentially exhausting the CD8+ T cell compartment and leading to immune compromise in older adults. It has been previously shown that IL-7Rα is expressed on T cells responding to acute viral infections such as influenza, but is not expressed on most CMV-specific T cells [23,33].

We showed that most of the GzmB+Perf+ effector T cell population responding to influenza virus, expressed IL-7Rα (CD127) suggesting that the dual expression of these cytolytic mediators could distinguish between terminally differentiated T cells and those T cells that could mount an effective influenza-specific cytolytic response to virus challenge. It should be noted that CD127+CD45RA+GzmB+Perf+ T cells are the phenotype of effector T cells in PBMC [24], which is maintained over the five days of in vitro stimulation and is the phenotype of T cell subset with demonstrated cytolytic activity in our experiments. This phenotype contrasts with the phenotype of CTL in the lungs, which have been activated by influenza-infected lung epithelial cells [23,24].

To determine a mechanism for increased susceptibility to serious complications of influenza infection, we identified the phenotype of cytolytic T cells. The effector T-cell subset (GzmB+Perf+CD45RA+CCR7−CD127+) that expressed IL-2R (CD25) had high proliferative capacity and effective virus-specific cytolytic function in healthy young adults. In contrast, the CD25− effector subset exhibited limited proliferation and diminished cytolytic function in response to influenza virus. The proliferative response that yielded IL-2R+ effector T cells following in vitro virus stimulation was dramatically reduced in both CD4+ and CD8+ T cells in older compared to young adults. This result is consistent with the previously identified age-related decline in the in vitro proliferative response, which is IL-2 mediated [35]. Differences in the serious complication rates of pH1N1 relative to A/H3N2 infection in young adults, and A/H3N2 and pH1N1 infection in older relative to young adults, may be explained by a reduction in both the proliferative and cytolytic responses to these influenza subtypes. These results may be helpful in understanding the limitations of split-virus vaccines for stimulating cross-reactive CTL responses, which could provide heterologous protection against different influenza subtypes and strains if effectively stimulated through vaccination.

Lower pH1N1 attack rates in older compared to young adults can be attributed to sterilizing immunity provided by pre-existing antibody titers. These antibodies may also contribute to a reduction in illness severity when infection occurs in older adults. In contrast, young adults would have lower antibody titers to pH1N1 but demonstrate a higher CD4+ and CD8+ effector T cell response to the virus following vaccination with the seasonal H1N1 strain (Fig. 4). Thus, the combined immunity provided by humoral and cellular mechanisms would explain the consistent case-fatality rates across the age spectrum and increases in these rates related to underlying high risk conditions in all age groups [36,37]. Protective antibody titers against pH1N1 were mainly observed in those adults over age 80 years old [38] and this was consistent with very low attack rates in this subset of older adults.

Current split-virus influenza vaccines stimulate a poor CTL response in both CD4+ and CD8+ subsets. For older adults in whom antibodies may not prevent influenza infection, the age-related decline in the memory and effector CTL response to influenza infection corresponds to the increased risk of complicated influenza illness in older adults. The marked decline in the CD8+ relative to the CD4+ T cell response to influenza vaccination is consistent with previous observations in vaccinia-challenged PBMC following smallpox vaccination [39−41]. Similar to our previous results showing no correlation between antibody titers and measures of cellular immunity, these earlier results showed no correlation between antibody titers and levels of vaccinia-specific CD4+ and CD8+ memory T cells [39]. In contrast, the decline in CD8+ memory T cells following smallpox vaccination appeared to be independent of age. Our results are consistent with an age-dependent effect on the duration of the response to influenza vaccination.

In light of the rapid loss of CD8+ T cell memory, we have identified CD4+ T cell subsets as a potential alternate target for designing new influenza vaccines. However, it remains to be determined whether novel influenza vaccines targeting the cell-mediated immune response could more fully realize the cytolytic potential of CD8+ T cells and improve protection in older adults. High dose influenza vaccines that would deliver more CD4 epitopes for antigen presentation may be one strategy. Alternatively, adjuvants that could more effectively present both CD4 and CD8 epitopes may offer an enhanced response in both T cell subsets. We have shown that older adults mount a very good GzmB response to infection [21] and this response can be re-stimulated upon influenza vaccination 8–10 months later [8]. However, it has yet to determine whether CD4+ and/or CD8+ T cells are the T cell subset responding to influenza infection in the lungs in humans. Importantly, the relevance of a CD4+ cytolytic T cell response to an enhanced response to influenza is dependent on the expression of MHC II and presentation of influenza epitopes on infected lung epithelial cells. It remains to be demonstrated whether these CD4+ T cells are functional cytolytic effectors that can clear influenza virus from the lungs in humans.

In summary, our results showed that age-related changes in CD8+ T cells are associated with severely compromised influenza virus-specific cytolytic activity. Current split-virus influenza vaccines provide a weak stimulus to the CTL response to influenza virus. In older compared to young adults, there is reduced cytolytic activity stimulated by influenza virus and the response to vaccination in CD8+ T cells appears short-lived. Effector CD4+ T cells in older adults appear to have preserved cytolytic function relative to CD8+ T cells, and may provide an alternate target for the development of more protective influenza vaccines in older people.

Acknowledgements

The authors thank the volunteers for their participation in the study, and the staff of the Lowell P. Weicker, Jr. General Clinical Research Center, UConn Center on Aging and the technicians in the McElhaney Laboratory for their assistance with subject recruitment, study co-ordination, and blood sample processing.

This work was sponsored by the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases, R01 AI68265 (J.E.M., Principal Investigator). The study was conducted through the Lowell P. Weicker, Jr. General Clinical Research Center
funded by the NIH, National Center for Research Resources (Grant Number M01 RR06192) at the University of Connecticut Health Center (UCHC), and in collaboration with the UConn Center on Aging.

Appendix A. Supplementary data

Supplementary data associated with this article can be found in the online version, at doi:10.1016/j.vaccine.2010.12.029.

References


[12] Lawrence CW, Ream RM, Braciale TJ. Frequency, specificity, and sites of expansion of CD8+ T cells during primary pulmonary influenza virus infection. J Immunol 2001;175(February (2)):342–51.


[16] Lawrence CW, Ream RM, Braciale TJ. Frequency, specificity, and sites of expansion of CD8+ T cells during primary pulmonary influenza virus infection. J Immunol 2001;175(February (2)):342–51.


[19] Lawrence CW, Ream RM, Braciale TJ. Frequency, specificity, and sites of expansion of CD8+ T cells during primary pulmonary influenza virus infection. J Immunol 2001;175(February (2)):342–51.


